Apply the power of OXISTAT® Lotion
OXISTAT® Lotion demonstrated greater efficacy in tinea pedis vs vehicle when dosed bid and qd1,2
Higher mycological cure rates with OXISTAT® Lotion in tinea pedis vs vehicle*1,2
(demonstrated 2 weeks post 4-week treatment)
Mycological cure1
- No evidence (culture and potassium hydroxide [KOH] preparation) of the original pathogen

Higher rates of treatment success with OXISTAT® Lotion in tinea pedis vs vehicle*1,2
(demonstrated 2 weeks post 4-week treatment)
Treatment success1
- Global evaluation of 90% clinical improvement
- Microbiological eradication

In a clinical trial of 269 patients treated with OXISTAT® Lotion, the most common adverse events were burning and stinging (0.7% each) and pruritus, scaling, tingling, pain, and dyshidrotic eczema (0.4% each).1
* In a clinical trial of OXISTAT® Lotion involving 332 evaluable patients with clinically and microbiologically established tinea pedis.1
References: 1. OXISTAT® Cream, OXISTAT® Lotion [Prescribing Information, 2012]. Melville, NY: PharmaDerm, a division of Fougera Pharmaceuticals Inc. 2. Data on file, Fougera.